# AbbVie: Phase 3 study closed enrollment, 89 enrolled (Hepatocellular Carcinoma)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | AbbVie |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) |
| NCT ID | NCT06109272 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Hepatocellular Carcinoma |
| Intervention types | drug |
| Target enrollment | 89 |
| Site countries | United States, France, Italy, Puerto Rico, Spain, Taiwan |
| Posted | 2023-10-31 |
| Planned start | 2024-01-11 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-22 |
| Last update posted | 2026-09-22 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06109272). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.